# Sacubitril/Valsartan for CKD5 Stage Dialysis Patients

Study · id `cardio:ct-nct05243199` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05243199](<https://clinicaltrials.gov/study/NCT05243199>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05243199

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 330 participants.

## Technical summary

Registry record NCT05243199. Randomized; no masking; primary purpose treatment. Start 2020-08-01 (actual); primary completion 2023-03-01 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 330 participants (enrolled count; ClinicalTrials.gov record NCT05243199, source copy `cardio:ctgov-nct05243199-2023-03-17`, retrieved 2026-10-26)
- Started: 2020-08-01 (actual) (ClinicalTrials.gov record NCT05243199, source copy `cardio:ctgov-nct05243199-2023-03-17`, retrieved 2026-10-26)
- Primary completion: 2023-03-01 (actual) (ClinicalTrials.gov record NCT05243199, source copy `cardio:ctgov-nct05243199-2023-03-17`, retrieved 2026-10-26)
- Completion: 2023-03-08 (actual) (ClinicalTrials.gov record NCT05243199, source copy `cardio:ctgov-nct05243199-2023-03-17`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT05243199, source copy `cardio:ctgov-nct05243199-2023-03-17`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05243199-2023-03-17`, retrieved 2026-10-26)

## The registry's words

- Brief title: Sacubitril/Valsartan for CKD5 Stage Dialysis Patients
- Condition: CKD5 Stage Dialysis
- Condition: Heart Failure
- Intervention (Drug): Sacubitril/Valsartan
- Intervention (Drug): Irbesartan
- Lead sponsor: Ruijin Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as the lead sponsor: Ruijin Hospital (`cardio:org-ruijin-hospital`)

## Provenance

Content hash: 4d05d61a26db011652db2f3a68ca1761aa9b8ebbc7987318acaa39ffbfdaf0cf
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
